))
Novel Molecular Targeting to Treat Neurodegenerative Disorders
Manage episode 285947415 series 2883917
Conteúdo fornecido por Disruption Everywhere Team. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Disruption Everywhere Team ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Currently, there are about 50 million people with Alzheimer’s, 50 million people with Dementia and 10 million people with Parkinson’s disease. Unfortunately, these disorders are difficult to treat, and many remain incurable. The existing treatments for Alzheimer’s (AD) have limited effectiveness and focus primarily on relieving symptoms rather than slowing the underlying disease. There is a major demand for new treatments, but despite significant efforts, few drug candidates have shown promising results. On this Disruption Everywhere podcast, we will be discussing how a protein called CDK5, has a significant influence on brain function, a key target for treating multiple neurodegenerative diseases with Dr. Kent Werner, Founder and CEO of Cogentis Therapeutics. Listen in on how Cogentis groundbreaking research discovers and develops first-in-class therapeutics that prevent neurodegeneration and restore brain function to benefit the lives of those patients and their families.
--- Support this podcast: https://podcasters.spotify.com/pod/show/disruptioneverywhere/support31 episódios
Compartilhar
